Provided by Tiger Fintech (Singapore) Pte. Ltd.

ESSA Pharma

1.79
+0.02001.13%
Post-market: 1.790.00000.00%16:49 EDT
Volume:177.60K
Turnover:314.99K
Market Cap:79.46M
PE:-2.55
High:1.81
Open:1.77
Low:1.73
Close:1.77
Loading ...

Essa Pharma downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
04 Nov 2024

ESSA Pharma Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $2 From $15

THOMSON REUTERS
·
04 Nov 2024

ESSA Pharma Inc : Jefferies Cuts to Hold From Buy

THOMSON REUTERS
·
04 Nov 2024

ESSA Pharma Faces Uncertainty After Discontinuing Masofaniten Programs, Receives Hold Rating

TIPRANKS
·
03 Nov 2024

Essa Pharma downgraded to Hold from Buy at Jefferies

TIPRANKS
·
02 Nov 2024

Top Midday Decliners

MT Newswires Live
·
02 Nov 2024

Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results

Benzinga
·
02 Nov 2024

Essa Pharma Cut to Hold From Buy by Jones Trading

Dow Jones
·
01 Nov 2024

ESSA Pharma tanks after terminating trial for its prostate cancer treatment

seekingalpha
·
01 Nov 2024

JonesTrading downgrades ESSA Pharma (EPIX) to a Hold

TIPRANKS
·
01 Nov 2024

Top Premarket Decliners

MT Newswires Live
·
01 Nov 2024

US Futures Rise Pre-Bell as Investors Await Key Employment, Manufacturing Data

MT Newswires Live
·
01 Nov 2024

Essa Pharma Shares Drop After Lead Drug Candidate Fails

Dow Jones
·
01 Nov 2024

ESSA Pharma Shares Decline Premarket Amid Termination of Phase 2 Trial on Masofaniten, Enzalutamide Combination

MT Newswires Live
·
01 Nov 2024

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
01 Nov 2024

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

CNW Group
·
01 Nov 2024

ESSA Pharma Insiders Placed Bullish Bets Worth US$709.0k

Simply Wall St.
·
28 Oct 2024